Literature DB >> 3955499

Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion.

H Martijn, H Schraffordt Koops, G W Milton, M Nap, J W Oosterhuis, H M Shaw, J Oldhoff.   

Abstract

A comparative retrospective study of patients with primary malignant melanomas of the extremities, Clark level IV/V and tumor thickness greater than or equal to 1.5 mm, was performed in Sydney (Australia) and Groningen (The Netherlands). The efficacy of wide local excision combined with adjuvant regional perfusion (Groningen) was compared with that of wide surgical excision only (Sydney). Patients were classified by sex and tumor location. There were only sufficient numbers of female patients with a tumor of the lower extremity available for this comparative study. All patients were stage I and none received prophylactic lymph node dissection. Age, tumor location, tumor thickness, depth of infiltration and ulceration were taken into account and the factors studied within this group were 10-year disease-free rate, 10-year survival rate, and local and regional recurrences. Women with a melanoma of the leg (excluding the foot) who had been treated by excision and adjuvant regional perfusion, had a significantly better 10-year disease-free rate (P less than 0.0005), a significantly higher 10-year survival rate (0.010 less than P less than 0.025) and significantly fewer local/regional recurrences (P less than 0.0005) than women treated by wide local excision only. For tumors of the foot, however, no significant differences in 10-year disease-free rate, 10-year survival rate or local/regional recurrences were observed after perfusion.

Entities:  

Mesh:

Year:  1986        PMID: 3955499     DOI: 10.1002/1097-0142(19860515)57:10<1923::aid-cncr2820571006>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Isolated regional perfusion in malignant melanoma of the extremities.

Authors:  H Schraffordt Koops; J Oldhoff; J W Oosterhuis; H Beekhuis
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

2.  Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.

Authors:  H Schraffordt Koops; B B Kroon; J Oldhoff; H J Hoekstra
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 3.  Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives.

Authors:  A M Eggermont; T L ten Hagen
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 4.  Cure and cosmesis in the management of primary malignant melanoma.

Authors:  G T Neades; L E Hughes
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

5.  Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines.

Authors:  T D Quinn; H C Polk; M J Edwards
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

6.  Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.

Authors:  H F Rauschecker; H Foth; H C Michaelis; F Horst; W Gatzemeier; C Willenbrock; E Voth; G F Kahl
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.